KCI Investor Presentation

Kinetic Concepts to

Acquire LifeCell

Creating a Platform

for Accelerated Growth

and Continued Innovation

Monday, April 7, 2008

9:00 a.m. EDT

Web Cast Presentation

Exhibit 99.1

Important Information

The tender offer described herein has not yet been commenced. The

description

contained

herein

neither

offer

purchase

nor

solicitation

of an offer to sell securities of LifeCell. At the time the tender offer is

commenced, Kinetic Concepts, Inc. (KCI) and its wholly-owned subsidiary

intend to file a Tender Offer Statement on Schedule TO containing an offer to

purchase, forms of letters of transmittal and other documents relating to the

tender offer, and LifeCell

intends to file a Solicitation/Recommendation

Statement on Schedule 14D-9 with respect to the tender offer. KCI, its wholly-

owned subsidiary and LifeCell

intend to mail these documents to the

stockholders of LifeCell. These documents will contain important information

about the tender offer, and stockholders of LifeCell

are urged to read them

carefully when they become available. Stockholders of LifeCell

will be able to

obtain a free copy of these documents (when they become available) and

other documents filed by LifeCell

or KCI with the SEC at the website

maintained by the SEC at www.sec.gov. In addition, stockholders will be able

to obtain a free copy of these documents (when they become available) from

by contacting the companies at the address specified on the Investor

Relations section of their respective websites.

Disclosure Regarding Forward

Looking Statements

Statements

presented

which

are

not

historical

facts,

including,

but

not

limited

to,

those

relating

revenue

growth,

financial

targets,

product

and

marketing

prospects,

and

product

demand,

are

forward-looking

statements

and

are

subject

variety

risks

and

uncertainties.

Many

factors

could

cause

actual

results

differ

materially

from

those

stated

projected.

Additional

information

concerning

these

factors

contained

the

Company’s

filings

with

the

Securities

and

Exchange

Commission.

The statements made in this presentation reflect facts and circumstances

as of April 7, 2008 and the Company does not undertake any duty to

update any statement, including any forward-looking statement, unless

required by law.

Catherine M. Burzik

President and Chief Executive Officer

Kinetic Concepts, Inc.

KCI’s Strategic Vision

A Growth-Oriented, Diversified, Global

Medtech Leader with Best-in-Class

Therapeutic Platforms

Enhance leadership position in large, underserved

markets

Rapidly commercialize innovative technologies to meet

unmet clinical needs

Sustain growth through global market leadership

Diversify revenues along multiple technology platforms

Increase shareholder value

Strategic Priorities:

LifeCell

Acquisition Rationale

AlloDerm

the

“Gold

Standard”

Tissue

Regeneration

Strattice™

(Reconstructive Tissue Matrix) is the next generation

growth platform

Proven proprietary technology

Meaningfully addresses revenue concentration

Enhances revenue and earnings growth momentum

Combines proven innovators with demonstrated track records

Best-in-class technologies combine for superior clinical outcomes

Substantial opportunities in the O.R. via new relationships

Ability to leverage KCI’s global infrastructure

Technology

Leader in

Large Growth

Market

Diversification

Attractive

Combined

Opportunity

LifeCell

the

right

strategic

fit

with

KCI’s

vision

and

provides

new

technology and a complementary business platform for growth

LifeCell

at a Glance

LifeCell

is the leader in the Tissue Regeneration market, with

a proven ability to develop and commercialize advanced

biological products made from human and animal dermis

Repair and

Reconstruction

Market

Orthopedics

Urogynecology

Other

12%

Market leader in high growth

segments

70%+ share of U.S. hernia

repairs using biologics

90%+ share of U.S. breast

reconstructions using biologics

Strong historical revenue and

earnings growth profile

Strattice

product expected to drive

future growth and profitability

LifeCell

Overview

2007A Revenue: $191mm

78%

Meaningful Revenue Diversification

Negative Pressure

Technology Platform

80%

Negative Pressure

Technology Platform

71%

Therapeutic Support

Systems

20%

Therapeutic Support

Systems

18%

LifeCell

11%

Pro Forma 2007 Revenue Profile

Compelling Operational Synergies

Leverage LifeCell’s

sales force to deliver current and

planned KCI products in the Operating Room

Utilize

KCI’s

sales

force

deliver

LifeCell

products

unserved

markets, such as in the treatment of chronic

wounds

Leverage and expand KCI’s international

infrastructure

launch

LifeCell’s

new

Strattice

technology in Europe

Existing Product Synergies

Today the products are used together to manage

complex clinical situations

Technological Synergies

Superior Tissue Repair and Regeneration

Negative Pressure

Technology Platform

Regeneration

Tissue Matrix

Create Optimal Healing

Environment

Reduce Fluid Build Up

Rapid Revascularization

Minimize Inflammation

Speed Cellular Repopulation

and Remodeling

Global Growth Strategy

U.S., Canada,

Germany, Austria,

Switzerland, Denmark

Japan, China,

India, Middle

East

U.K., Italy, France, Spain,

S. Africa, Norway, Sweden,

Finland, Australia,

Singapore, S. Korea

KCI Maintains an Expanding Global Market Presence

Paul Thomas

Chairman, President and Chief Executive Officer

LifeCell

Marty Landon

Sr. Vice President and Chief Financial Officer

Kinetic Concepts, Inc.

Basic Transaction Terms

$1.7 billion in cash

$51.00

per

LifeCell

stock

By end of Q2 2008

Purchase

Price

Consideration

Estimated

Closing

Compelling Financial Profile

Meaningful

Revenue

Diversification

Accelerated

Revenue &

Earnings

Momentum

Improved

Margin Profile

~ $200 million revenue base in

$1B+ tissue regeneration market

2007 revenue growth of ~ 35% with

highly anticipated Strattice

introduction in 2008

2007 EPS growth ~ 35%

Enhances an already strong

margin structure

Strong Post Closing Balance Sheet

Manageable

Leverage

Level

Rapid

Delevering

Strategy

Pro forma leverage of ~ 2.9x

EBITDA at closing

Strong cash flow reduces

leverage below 1.0x EBITDA in 2010

Brief Dilution Period Provides

Rapid Value Creation

Cash EPS

GAAP EPS

Becomes accretive in 2009

Significantly accretive 2010

and thereafter

Becomes accretive in 2010

Significantly accretive 2011

and thereafter

Catherine M. Burzik

President and Chief Executive Officer

Kinetic Concepts, Inc.

Summary

Substantial revenue growth and diversification

Combines market leaders with best-in-class

technologies

Opportunity for O.R. Penetration

Expand LifeCell

platform to KCI’s U.S.

hospital relationships

Drive international penetration through

KCI’s global infrastructure

Combined product development pipelines

will create new clinical solutions

Question and Answer